https://www.selleckchem.com/pr....oducts/Belinostat.ht
The frequency of Granzyme-B and Interferon-γ producing TEMRAs was also higher in responding patients. High proportions of TEMRAs and cytokine production by TEMRAs before treatment, was associated with a better clinical outcome. TEMRAs, which likely comprise tumor-specific T cells, tend to require blockage of both aPD-1 and aCTLA-4 to be reactivated. In conclusion, peripheral blood TEMRAs can play a key role in explaining and predicting clinical benefit upon aPD-1/aCTLA-4 combination treatment. Bristol-Myers Squibb sponsored NivoMes a